Nih
Nih funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
RFA-HD-27-012: Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)
A limited-competition NIH renewal for existing NICHD IDDRCs, this NOFO funds interdisciplinary P50 centers advancing translational, biomarker, and real-world research for intellectual and developmental disabilities.
RFA-HG-25-009: Supporting Talented Early Career Researchers in Genomics (R01)
NIH/NHGRI reissues an R01-style NOFO for highly promising Early Stage Investigators (ESIs) building independent genomics programs, with a maximum direct-cost budget of $400,000 per year and up to a five-year project term.
RFA-HL-26-002: NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
The NHLBI Outstanding Investigator Award provides up to 7 years of flexible R35 support, with applications requesting up to $700,000 in direct costs per year, for established investigators whose programs advance heart, lung, blood, and sleep research.
RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)
NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.
RFA-HL-26-012: NIH StARR (R38) 2026-2027 Funding for Residency Research Programs
NIH StARR (R38) supports residency programs that give postdoctoral-level clinicians mentored research time and a path toward clinician-investigator careers.
RFA-HL-26-016: Catalyze Enabling Technologies and Transformative Platforms for HLBS Research (R33)
The National Heart, Lung, and Blood Institute's Catalyze R33 supports further development and rigorous validation of transformative, multi-use technologies and platforms relevant to heart, lung, blood, and sleep research. The next listed application due date is 2026-10-21.
RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)
NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.
RFA-HL-26-018: Catalyze Product Definition for Small Molecules, Biologics, and Combination Products
An NIH R33 Catalyze Product Definition NOFO for early translational work that identifies a lead compound series and tests a combination-product prototype for heart, lung, blood, and sleep diseases. The next announced application date is October 21, 2026.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33; Clinical Trial Not Allowed)
NIH NHLBI Catalyze Product Definition NOFO for early-stage device, diagnostic, and research-tool development in heart, lung, blood, and sleep diseases. The next new-application due date is October 21, 2026.
RFA-HL-26-020: Catalyze: Product Definition Medical Device Prototype Optimization (R33)
NHLBI Catalyze RFA-HL-26-020 funds late-stage prototype optimization for medical devices, diagnostics, and research tools for heart, lung, blood, and sleep disorders via R33 awards.